DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
1 February 2019
A new research paper recently published by the AFD (Agence Française de Développement) examines how DNDi, a distinctive Product Development Partnership (PDP), can illustrate what can be presented as a “commons” in the area of public health.
TiaSáng [31 January 2019]
“Tài trợ cho nghiên cứu về những “căn bệnh bị lãng quên” tăng cao kỷ lục” – “Neglected disease research funding hits record high”
Mundiario [25 January 2019]
“La financiación de la investigación de enfermedades desatendidas alcanza un récord” – “Funding for research on neglected diseases reaches a record”
Nature [23 January 2019]
“Neglected disease research funding hits record high”
23 January 2019
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.
Estadão [23 January 2019]
“Investimento do País em doenças negligenciadas cai 42% entre 2016 e 2017” – “Country investment in neglected diseases fell 42% between 2016 and 2017”
15 November 2018
On November 15, 2018, members of the Chagas Clinical Research Platform and the Global Chagas Coalition, participating in the VIII Meeting of the Chagas Platform in Santa Cruz de la Sierra, Bolivia, signed this letter addressed to governments, organizations and donors requesting an intensification in the efforts to control and eliminate Chagas disease as a public health problem. In the last 10 years, there have been significant efforts in the fight against the disease. However, many challenges remain. Next 2019 marks the 110th anniversary since the discovery of the disease and constitutes an opportunity to call attention to people affected by the disease and pursue necessary actions.
Healio [8 April 2018]
“International partnership invests $15.5 million to combat neglected tropical diseases, TB, malaria”
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and Chagas disease.